ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    MMY3011
Previous Study | Return to List | Next Study

A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT03217812
Recruitment Status : Recruiting
First Posted : July 14, 2017
Last Update Posted : June 29, 2018
Sponsor:
Information provided by (Responsible Party):
Janssen Research & Development, LLC

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Recruiting
  Estimated Primary Completion Date : January 17, 2020
  Estimated Study Completion Date : October 31, 2022